Shares in Cerus (NSDQ:CERS) fell today despite the company beating expectations on Wall Street with its second quarter results. The Concord, Calif.-based company posted a net loss of -$17.1, or -16¢ per share, on sales of $9.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales growth of 3% compared […]
Cerus Corporation
Cerus inks $40m loan deal with Oxford Finance
Cerus (NSDQ:CERS) said today that it inked a $40 million amended growth capital credit facility with Oxford Finance. Concord, Calif.-based Cerus received a $30 million loan when it closed the deal, according to the company, and can draw another $10 million contingent upon a specified sales milestone. “Oxford continues to be an invaluable partner. Their appreciation […]
Cerus lowers Intercept sales guidance after Fresenius Kabi supply snafu
Cerus (NSDQ:CERS) said today that it expects a U.S. supply shortage of Fresenius Kabi’s (NYSE:FMS) platelet additive solution will impact blood centers that use PAS to produce Intercept platelets. The pending shortage is due to “an unanticipated delay” in FDA approval of a plastic component used to manufacture the PAS container. The original component was discontinued […]
First patient transfused with Intercept red blood cells in Phase III trial
Cerus (NSDQ:CERS) said today that the 1st patient was transfused in Puerto Rico in a clinical trial comparing red blood cells processed with its Intercept blood system to conventional red blood cells. Concord, Calif.-based Cerus is developing the Intercept blood system, a pathogen reduction device designed to inactivate a broad range of viruses, bacteria, parasites […]
Cerus lands $47m for Intercept red blood cell system
Cerus (NSDQ:CERS) said today that it exercised $46.6 million in additional options from its contract with the Biomedical Advanced Research & Development Authority, a part of the U.S. Dept. of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. Concord, Calif.-based Cerus is developing the Intercept blood system, a pathogen reduction device designed […]
Cerus shares fall after Q1 miss
Shares in Cerus Corp. (NSDQ:CERS) fell -18% today after the company missed expectations on Wall Street with its 1st quarter results. The Concord, Calif.-based company posted a net loss of -$18.7 million, or -18¢ per share, on sales of $7 million for the 3 months ended March 31, for bottom-line loss of -10.7% on sales growth of […]
Cerus raises funds for phase III trial of Intercept red blood cell system
Cerus Corporation (NSDQ:CERS) said today that it exercised $10.8 million in additional options from its contract with the Biomedical Advanced Research & Development Authority, a part of the U.S. Dept. of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The funds will go towards in vitro pathogen inactivation and red blood cell […]